Creating New Treatment Options for Patients Through the Activation & Redirection of Innate Immune Cells

Time: 10:10 am
day: Day Two


  • Highlighting how tumor immune evasion strategies lead to disarming of innate immunity by the tumor
  • Demonstrating that through the activation and redirection of innate immune cells, innate cell engagers (ICEs) can restore immunosurveillance providing clinical benefit in heavily pre-treated patients suffering from hematological malignancies
  • High NK cell counts prior and during treatment with ICEs is a common feature of responsive patients
  • Outlining that the combination of immune cell engagers with adoptive NK cell transfer holds promise to provide additional benefit in a broad set of patients including hematological and solid malignancies